Stock Events

Stock Events

Royalty Pharma 

$63.96
397
+$0.08+0.13% 20:00 Today
-$3.46-5.41%21:59After hours

Statistics

Day High
64.38
Day Low
63.43
52W High
64.38
52W Low
34.08
Volume
3,372,439
Avg. Volume
3,056,525
Mkt Cap
28.48B
P/E Ratio
29.7
Dividend Yield
1.47%
Dividend
0.94

Upcoming

Dividends

1.47%Dividend Yield
Sep 26
$0.24
Jun 26
$0.24
Mar 26
$0.24
Dec 25
$0.22
Sep 25
$0.22
10Y Growth
N/A
5Y Growth
7.29%
3Y Growth
5.27%
1Y Growth
5.81%

Earnings

11NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0.75
0.99
1.23
1.47
Expected EPS
1.170723
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
770.95MNet Income

Analyst Ratings

62.60Average Price Target
The highest estimate is 66.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPRX. It's not an investment recommendation.
NVIDIA
57
NVDA
Apple
56
AAPL
Coca-Cola
55
KO
Microsoft
52
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Royalty Pharma in the acquisition and management of pharmaceutical royalties, particularly through its string of acquisitions that expand its portfolio in similar therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company that competes with Royalty Pharma in the development and commercialization of medical treatments, and it also engages in deals and partnerships that involve royalty agreements.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the research, development, and commercialization of drugs in areas like HIV/AIDS, liver diseases, and oncology, competing with Royalty Pharma in acquiring royalties in these therapeutic areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the pharmaceutical industry, focusing on acquiring and developing a portfolio of medicines, directly competing with Royalty Pharma in the market for drug royalties and investments in pharmaceutical innovations.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that competes with Royalty Pharma through its extensive drug development programs and partnerships that may involve royalty financing and agreements.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals. Its involvement in drug development and royalty agreements places it in competition with Royalty Pharma.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company, competing with Royalty Pharma in the acquisition of drug royalties and through its focus on innovative drug development.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is a global healthcare leader that competes with Royalty Pharma in the pharmaceutical sector, particularly through its efforts to secure drug royalties and its focus on innovative treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that competes with Royalty Pharma through its significant investments in drug development and its strategy to acquire and manage drug royalties.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Royalty Pharma in the market for pharmaceutical royalties, especially in the generic sector where royalties are a key component of profitability.

About

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Show more...
CEO
Pablo Legorreta
Employees
100
Country
United Kingdom
ISIN
GB00BMVP7Y09
WKN
000A2P62D

Listings

XETRA
DE
RPD.XETRA
MX
MX
RPRXN.MX
MU
DE
RPD.MU
STU
DE
RPD.STU

0 Comments

Share your thoughts

FAQ

What is Royalty Pharma stock price today?▼
The current price of RPRX is $63.96 USD — it has increased by +0.13% in the past 24 hours. Watch Royalty Pharma stock price performance more closely on the chart.
What is Royalty Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Royalty Pharma stocks are traded under the ticker RPRX.
Is Royalty Pharma stock price growing?▼
RPRX stock has risen by +5.11% compared to the previous week, the month change is a +11.27% rise, over the last year Royalty Pharma has showed a +73.33% increase.
What is Royalty Pharma market cap?▼
Today Royalty Pharma has the market capitalization of 28.48B
When is the next Royalty Pharma earnings date?▼
Royalty Pharma is going to release the next earnings report on November 11, 2026.
What were Royalty Pharma earnings last quarter?▼
RPRX earnings for the last quarter are 1.32 USD per share, whereas the estimation was 1.27 USD resulting in a +3.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Royalty Pharma revenue for the last year?▼
Royalty Pharma revenue for the last year amounts to 0 USD.
What is Royalty Pharma net income for the last year?▼
RPRX net income for the last year is 770.95M USD.
Does Royalty Pharma pay dividends?▼
Yes, RPRX dividends are paid quarterly. The last dividend per share was 0.24 USD. As of today, Dividend Yield (FWD)% is 1.47%.
How many employees does Royalty Pharma have?▼
As of September 04, 2026, the company has 100 employees.
In which sector is Royalty Pharma located?▼
Royalty Pharma operates in the Health & Wellness sector.
When did Royalty Pharma complete a stock split?▼
The last stock split for Royalty Pharma was on October 15, 2010 with a ratio of 1:4.
Where is Royalty Pharma headquartered?▼
Royalty Pharma is headquartered in NEW YORK, United Kingdom.